|
Semafore Pharmaceuticals is signaling its arrival on the oncology drug making scene. The development-stage drug discovery company is targeting the PI3K cell signaling pathways to create anti-cancer drugs. Its PI3K Inhibitors induce the death of cancerous cells in the treatment of tumors and could potentially treat brain, lung, and hematological cancers. Once administered, its lead candidate SF1126 attacks proteins expressed in tumors, but ignores healthy cells. Semafore has brought on a consulting firm to help shepherd SF1126 -- in early stage clinical trials -- through its next stage of development. In the company's preclinical pipeline is SF2626, which is also being tested for its ability inhibit P13K.
|
| | | Contact Information | |
Address: |
17338 Westfield Park Rd., Ste. 3
Westfield, IN 46074
| | Phone: | 317-867-1126 | | Fax: | 317-867-1127 |
|
|
Key People
| | • |
CEO:
L. Dennis McKeever
| | • |
President, COO, and Director:
John Sima
|
|
|
